Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. - Wikidata - awgldk - TriplyDB

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q33384455

about

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations Optimizing the management of advanced non-small-cell lung cancer: a personal view Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review Recent Advances in Immunotherapy in Metastatic NSCLC Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)The Lake Wobegon effect: are all cancer patients above average?International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma Increased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trials Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer.Efficacies and adverse reactions of modified vitamin supplement programs before pemetrexed chemotherapy as a second-line treatment against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma.A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer.Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules.Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach.[A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer].A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.Pemetrexed in advanced non-small-cell lung cancer.Pemetrexed in advanced non-small cell lung cancer.Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer.Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials.Review of the treatment of metastatic non small cell lung carcinoma: A practical approach The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.Treatment of advanced non small cell lung cancer.

P2860

Q21132357-0D17FC98-F56F-4DC4-B84A-11D9B50B4CFD Q24656144-3B9072E4-D872-4186-8597-6CD2F8A3A923 Q26745422-472FF99A-DDD6-4FAD-B902-DEEFA4E9C7A2 Q26781856-3CF48D19-EE0F-4515-9746-5008A62CE86D Q28068435-3C0BC1AF-EB78-44FF-909B-6A25C6127CBC Q28069323-E049E197-67C3-416A-A0C0-6D2CE4637644 Q28081243-30C3059B-A380-4C59-B328-DBD5B4DD2A03 Q28303620-4339ED82-CB6F-4BDC-ADE5-A55CFF6834A3 Q28303718-87D166A3-FDCF-4111-9295-41CECA6B62EF Q28533753-F73D3DDD-363E-493F-BF8E-CDF798523D88 Q30356434-A5C1AEAC-14CC-435C-8A42-3DA62C52B5C7 Q30400310-F90FFD83-5338-405B-B94F-FD4D729DB8AD Q33392085-6C6103DB-C8C8-4A52-B7DC-729B3DD6DDDD Q33397163-603412F9-1C16-435E-9840-F96AA6E45D90 Q33402098-700D7F88-F5CF-44A5-9A9C-D24875E7C2D2 Q33402765-032B5BE5-FA5C-4304-9F91-8544FF1604B6 Q33403234-0D27E594-CDAE-4F17-9B78-BD911564F922 Q33414360-43B70CA2-5A23-41B8-8EFC-51D28958F880 Q33424102-FD9A1563-BB9A-42A6-B64F-545616ABED69 Q33427414-F640BF82-866A-49BD-AAB5-0EB069AB0E69 Q33427832-0DCDD500-D716-4222-A5E4-7520593A25FC Q33429178-1B4945E8-3DD0-4A7C-82DA-387B2145B575 Q33430977-E40E1064-C8E0-4D55-AE99-21ADBAF65A5A Q33439985-695B5BED-2B94-4E63-81AE-1129EA5B52DC Q33754141-AC6ADC13-ACBE-46A8-A72A-8119F6A8F922 Q33789357-27FCBFA1-2E0F-4052-A4E6-392C2DB62F30 Q33789669-E2AE45DF-EA33-435C-BAA7-B46F9A85395A Q33911180-02D11CDC-920E-4110-B2E3-DE5153D6D85F Q34005272-2A52F056-F638-44F9-A639-304D97D86E94 Q34113895-AF283A4F-AEB8-47F4-BF5B-9B94D59CC1D8 Q34160513-18169612-B338-4E65-B4A9-BDF1CE80D449 Q34277874-E04B4653-7F83-4275-991B-8546C9339584 Q34781002-6234A0BD-2A6D-426F-8859-F505776933A5 Q35015020-7E01CB06-6ED1-4436-8889-291FA69744ED Q35109837-5F8D1AF5-D590-4687-9DBB-9C61BD28ED71 Q35111780-58074EB4-79CA-41FD-B163-F6B617176BFD Q35113397-68E307DD-A280-49EB-B828-19368E98557C Q35290441-74A30D4D-BF96-4AC6-A814-5D291E705C59 Q35557605-9A272402-F25F-4136-B148-0E1AAA3E1A10 Q35667817-E8BD9EBF-EDDF-40CD-A26E-AF1BCE5769D9

P2860

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q33384455

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase III study by the Norwegi ...... ed non-small-cell lung cancer.

@ast

Phase III study by the Norwegi ...... ed non-small-cell lung cancer.

@en

type

label

Phase III study by the Norwegi ...... ed non-small-cell lung cancer.

@ast

Phase III study by the Norwegi ...... ed non-small-cell lung cancer.

@en

prefLabel

Phase III study by the Norwegi ...... ed non-small-cell lung cancer.

@ast

Phase III study by the Norwegi ...... ed non-small-cell lung cancer.

@en

P1433

Q33384455-1A29E7CC-E4C3-4BFE-9FE3-E7F9D0165590

P1476

Q33384455-41078EED-8F3F-4C85-B1E3-69CE97493CD2

P2093

Q33384455-143016F0-3117-42CB-AC03-6DF1B376C571

Q33384455-27C858F4-0056-4524-9810-F87C6F25A796

Q33384455-326AED1C-77B0-4CBE-B073-8215A55F1FB9

Q33384455-6814B37F-F756-4F3F-BC72-228DFC8C931D

Q33384455-6989698C-F127-4839-8FFC-8FC3C1B05155

Q33384455-B466A2F5-99D7-4BB3-A292-13697F344D5E

Q33384455-BDF9657C-35D9-4245-881A-9D941372025E

Q33384455-C160DF93-FD02-4A71-8A5C-E4A302911CC0

Q33384455-CBEB7272-0F5A-4E1F-8328-A14325CC7AEB

Q33384455-D3BFDBCA-8D58-4B48-AEAB-726F7F42D2E2

P304

Q33384455-B666E7AF-C5D7-4DB0-BB8F-C12411FA5779

P31

Q33384455-C6FF1C2F-3B80-4017-8D92-CB5BA7105D2C

P356

Q33384455-E35DBF3F-986B-4112-9412-F45941980DF9

P407

Q33384455-9969C56D-4F38-426A-A7E3-A5C1522B575C

P433

Q33384455-D80F1432-14E2-4346-82FF-DD8CB75489B4

P478

Q33384455-E84E8687-1ED8-4EC7-A953-D444BF6CECCB

P50

Q33384455-1687E3B2-F9AC-4093-BF3C-B6EA3F3533C1

Q33384455-6ABF4A4C-496D-4F26-A876-3D9B72D30A72

P577

Q33384455-6D4F819B-9050-44CA-A305-2EC16495B705

P698

Q33384455-9A5FA5E9-69ED-48C6-950A-07DB40D516F2

P921

Q33384455-E5FF18C4-D5ED-41BF-AEB6-14E58621379F

P356

JCO.2008.20.9114

P1433

Journal of Clinical Oncology

P1476

Phase III study by the Norwegi ...... ed non-small-cell lung cancer.

@en

P2093

Bjørn H Grønberg

http://www.w3.org/2001/XMLSchema#string

Christian von Plessen

http://www.w3.org/2001/XMLSchema#string

Finn Wammer

http://www.w3.org/2001/XMLSchema#string

Frøydis Stornes

http://www.w3.org/2001/XMLSchema#string

Harald H Hjelde

http://www.w3.org/2001/XMLSchema#string

Paal Fr Brunsvig

http://www.w3.org/2001/XMLSchema#string

Roy M Bremnes

http://www.w3.org/2001/XMLSchema#string

Stein Sundstrøm

http://www.w3.org/2001/XMLSchema#string

Terje Tollåli

http://www.w3.org/2001/XMLSchema#string

Tore Amundsen

http://www.w3.org/2001/XMLSchema#string

P304

3217-3224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.9114

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Øystein Fløtten

P577

2009-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19433683

http://www.w3.org/2001/XMLSchema#string

P921